Tscan Therapeutics Inc (TCRX) Is Becoming Less Appealing To Investors After A 19.86% Rise
Tscan Therapeutics Inc (NASDAQ:TCRX) has a beta value of 0.97 and has seen 1.18 million shares traded in the last trading session. The company, currently
Tscan Therapeutics Inc (NASDAQ:TCRX) has a beta value of 0.97 and has seen 1.18 million shares traded in the last trading session. The company, currently
During the last session, Tscan Therapeutics Inc (NASDAQ:TCRX)’s traded shares were 0.44 million, with the beta value of the company hitting 0.99. At the end
In the last trading session, 1.08 million shares of the Tscan Therapeutics Inc (NASDAQ:TCRX) were traded, and its beta was 1.00. Most recently the company’s
In the last trading session, 3.92 million Tscan Therapeutics Inc (NASDAQ:TCRX) shares changed hands as the company’s beta touched 0.89. With the company’s per share
In last trading session, Tscan Therapeutics Inc (NASDAQ:TCRX) saw 0.31 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price
Tscan Therapeutics Inc (NASDAQ:TCRX)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 1.06. At the close of
© 2024, Powered by Smart TechOne